Ligand Pharmaceuticals (LGND) Other financing activities (2020 - 2026)

Ligand Pharmaceuticals has disclosed Other financing activities across 6 years of filings, most recently posting $50000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $50000.0, down 29.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.5 million (up 3300.66% YoY), and the FY2025 annual result was $15.5 million, up 3545.07% from the prior year.
• Other financing activities came in at $50000.0 for Q1 2026 at Ligand Pharmaceuticals, down from $617000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $14.8 million in Q3 2025 to a low of -$121000.0 in Q1 2022.
• The 5-year median for Other financing activities is $64000.0 (2024), against an average of $1.2 million.
• Peak annual rise in Other financing activities reached 6965.71% in 2025, while the deepest fall reached 96.49% in 2025.
• Ligand Pharmaceuticals' Other financing activities stood at $42000.0 in 2022, then jumped by 2159.52% to $949000.0 in 2023, then plunged by 87.57% to $118000.0 in 2024, then jumped by 422.88% to $617000.0 in 2025, then sank by 91.9% to $50000.0 in 2026.
• The last three Other financing activities figures came in at $50000.0 (Q1 2026), $617000.0 (Q4 2025), and $14.8 million (Q3 2025), per Business Quant data.